An Emerging Cardiovascular Disease: Takotsubo Syndrome

Sara Moscatelli, Fabrizio Montecucco, Federico Carbone, Alberto Valbusa, Laura Massobrio, Italo Porto, Claudio Brunelli, Gian Marco Rosa

Research output: Contribution to journalReview article

Abstract

Takotsubo syndrome (TTS) is a recently identified cardiac disease, which is far from being completely known. The aims of this narrative review are to provide a better understanding of the pathophysiological features of TTS and to update clinical findings in order to improve the management of subjects affected by this syndrome (according to the most recent consensus papers issued by the international scientific societies). We based our search on the material obtained via PubMed up to April 2019. The terms used were "Takotsubo Syndrome and Takotsubo cardiomyopathy" in combination with "heart failure, pathophysiology, complications, diagnosis, and treatment." TTS is a reversible form of ventricular dysfunction usually characterized by akinesia of the apex in the absence of obstructive coronary artery disease. In its initial phase, TTS may be indistinguishable from AMI and is usually triggered by a sudden emotional/physical stressor which abruptly increases catecholamine levels. However, the mechanisms by which catecholamines or other unidentified molecules can cause myocardial dysfunction is unknown. In-hospital stay may be hampered by various life-threatening complications, while data on long-term survival remain scarce and unclear. Furthermore, TTS may sometimes recur. We believe that TTS is clearly a much more complex condition than previously thought. Much remains to be discovered about its pathophysiologic mechanisms, the role of the link between the heart and brain and that of triggering factors and gender, and the reasons why this syndrome displays different phenotypes and sometimes recurs. Undoubtedly, preliminary evidence from pathophysiological studies (mainly genetic studies) has shown promising advances. However, prospective randomized clinical trials are still needed in order to identify and to tailor the best medical treatments for TTS patients.

Original languageEnglish
Article number6571045
JournalBioMed Research International
Volume2019
DOIs
Publication statusPublished - Oct 30 2019

Fingerprint

Takotsubo Cardiomyopathy
Catecholamines
Cardiovascular Diseases
Brain
Molecules
Ventricular Dysfunction
PubMed
Coronary Artery Disease
Heart Diseases
Length of Stay
Randomized Controlled Trials
Heart Failure
Phenotype

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Moscatelli, S., Montecucco, F., Carbone, F., Valbusa, A., Massobrio, L., Porto, I., ... Rosa, G. M. (2019). An Emerging Cardiovascular Disease: Takotsubo Syndrome. BioMed Research International, 2019, [6571045]. https://doi.org/10.1155/2019/6571045

An Emerging Cardiovascular Disease : Takotsubo Syndrome. / Moscatelli, Sara; Montecucco, Fabrizio; Carbone, Federico; Valbusa, Alberto; Massobrio, Laura; Porto, Italo; Brunelli, Claudio; Rosa, Gian Marco.

In: BioMed Research International, Vol. 2019, 6571045, 30.10.2019.

Research output: Contribution to journalReview article

Moscatelli, S, Montecucco, F, Carbone, F, Valbusa, A, Massobrio, L, Porto, I, Brunelli, C & Rosa, GM 2019, 'An Emerging Cardiovascular Disease: Takotsubo Syndrome', BioMed Research International, vol. 2019, 6571045. https://doi.org/10.1155/2019/6571045
Moscatelli S, Montecucco F, Carbone F, Valbusa A, Massobrio L, Porto I et al. An Emerging Cardiovascular Disease: Takotsubo Syndrome. BioMed Research International. 2019 Oct 30;2019. 6571045. https://doi.org/10.1155/2019/6571045
Moscatelli, Sara ; Montecucco, Fabrizio ; Carbone, Federico ; Valbusa, Alberto ; Massobrio, Laura ; Porto, Italo ; Brunelli, Claudio ; Rosa, Gian Marco. / An Emerging Cardiovascular Disease : Takotsubo Syndrome. In: BioMed Research International. 2019 ; Vol. 2019.
@article{07c7b389154740cab6b971cb6d301bca,
title = "An Emerging Cardiovascular Disease: Takotsubo Syndrome",
abstract = "Takotsubo syndrome (TTS) is a recently identified cardiac disease, which is far from being completely known. The aims of this narrative review are to provide a better understanding of the pathophysiological features of TTS and to update clinical findings in order to improve the management of subjects affected by this syndrome (according to the most recent consensus papers issued by the international scientific societies). We based our search on the material obtained via PubMed up to April 2019. The terms used were {"}Takotsubo Syndrome and Takotsubo cardiomyopathy{"} in combination with {"}heart failure, pathophysiology, complications, diagnosis, and treatment.{"} TTS is a reversible form of ventricular dysfunction usually characterized by akinesia of the apex in the absence of obstructive coronary artery disease. In its initial phase, TTS may be indistinguishable from AMI and is usually triggered by a sudden emotional/physical stressor which abruptly increases catecholamine levels. However, the mechanisms by which catecholamines or other unidentified molecules can cause myocardial dysfunction is unknown. In-hospital stay may be hampered by various life-threatening complications, while data on long-term survival remain scarce and unclear. Furthermore, TTS may sometimes recur. We believe that TTS is clearly a much more complex condition than previously thought. Much remains to be discovered about its pathophysiologic mechanisms, the role of the link between the heart and brain and that of triggering factors and gender, and the reasons why this syndrome displays different phenotypes and sometimes recurs. Undoubtedly, preliminary evidence from pathophysiological studies (mainly genetic studies) has shown promising advances. However, prospective randomized clinical trials are still needed in order to identify and to tailor the best medical treatments for TTS patients.",
author = "Sara Moscatelli and Fabrizio Montecucco and Federico Carbone and Alberto Valbusa and Laura Massobrio and Italo Porto and Claudio Brunelli and Rosa, {Gian Marco}",
year = "2019",
month = "10",
day = "30",
doi = "10.1155/2019/6571045",
language = "English",
volume = "2019",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - An Emerging Cardiovascular Disease

T2 - Takotsubo Syndrome

AU - Moscatelli, Sara

AU - Montecucco, Fabrizio

AU - Carbone, Federico

AU - Valbusa, Alberto

AU - Massobrio, Laura

AU - Porto, Italo

AU - Brunelli, Claudio

AU - Rosa, Gian Marco

PY - 2019/10/30

Y1 - 2019/10/30

N2 - Takotsubo syndrome (TTS) is a recently identified cardiac disease, which is far from being completely known. The aims of this narrative review are to provide a better understanding of the pathophysiological features of TTS and to update clinical findings in order to improve the management of subjects affected by this syndrome (according to the most recent consensus papers issued by the international scientific societies). We based our search on the material obtained via PubMed up to April 2019. The terms used were "Takotsubo Syndrome and Takotsubo cardiomyopathy" in combination with "heart failure, pathophysiology, complications, diagnosis, and treatment." TTS is a reversible form of ventricular dysfunction usually characterized by akinesia of the apex in the absence of obstructive coronary artery disease. In its initial phase, TTS may be indistinguishable from AMI and is usually triggered by a sudden emotional/physical stressor which abruptly increases catecholamine levels. However, the mechanisms by which catecholamines or other unidentified molecules can cause myocardial dysfunction is unknown. In-hospital stay may be hampered by various life-threatening complications, while data on long-term survival remain scarce and unclear. Furthermore, TTS may sometimes recur. We believe that TTS is clearly a much more complex condition than previously thought. Much remains to be discovered about its pathophysiologic mechanisms, the role of the link between the heart and brain and that of triggering factors and gender, and the reasons why this syndrome displays different phenotypes and sometimes recurs. Undoubtedly, preliminary evidence from pathophysiological studies (mainly genetic studies) has shown promising advances. However, prospective randomized clinical trials are still needed in order to identify and to tailor the best medical treatments for TTS patients.

AB - Takotsubo syndrome (TTS) is a recently identified cardiac disease, which is far from being completely known. The aims of this narrative review are to provide a better understanding of the pathophysiological features of TTS and to update clinical findings in order to improve the management of subjects affected by this syndrome (according to the most recent consensus papers issued by the international scientific societies). We based our search on the material obtained via PubMed up to April 2019. The terms used were "Takotsubo Syndrome and Takotsubo cardiomyopathy" in combination with "heart failure, pathophysiology, complications, diagnosis, and treatment." TTS is a reversible form of ventricular dysfunction usually characterized by akinesia of the apex in the absence of obstructive coronary artery disease. In its initial phase, TTS may be indistinguishable from AMI and is usually triggered by a sudden emotional/physical stressor which abruptly increases catecholamine levels. However, the mechanisms by which catecholamines or other unidentified molecules can cause myocardial dysfunction is unknown. In-hospital stay may be hampered by various life-threatening complications, while data on long-term survival remain scarce and unclear. Furthermore, TTS may sometimes recur. We believe that TTS is clearly a much more complex condition than previously thought. Much remains to be discovered about its pathophysiologic mechanisms, the role of the link between the heart and brain and that of triggering factors and gender, and the reasons why this syndrome displays different phenotypes and sometimes recurs. Undoubtedly, preliminary evidence from pathophysiological studies (mainly genetic studies) has shown promising advances. However, prospective randomized clinical trials are still needed in order to identify and to tailor the best medical treatments for TTS patients.

UR - http://www.scopus.com/inward/record.url?scp=85075154587&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075154587&partnerID=8YFLogxK

U2 - 10.1155/2019/6571045

DO - 10.1155/2019/6571045

M3 - Review article

AN - SCOPUS:85075154587

VL - 2019

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 6571045

ER -